AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2021
Jul 13, 2021
31542_dirs_2021-07-13_ca236068-9929-4ec4-bcc4-f1156e633670.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2021-07-06
Reporting Person: Sundaram Preethi (Chief Product Devel. Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Options to purchase Common Stock | $5.49 | 2028-07-06 | Common Stock (300000) | Direct |
Footnotes
F1: Options will vest in four equal tranches on July 6, 2022, 2023, 2024 and 2025.
More from CATALYST PHARMACEUTICALS, INC.
M&A Activity
2026
Jun 8
Report Publication Announcement
2026
May 11
M&A Activity
2026
May 7
Major Shareholding Notification
2026
Mar 26
Earnings Release
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Investor Presentation
2026
Jan 12
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6